Does Adderall XR Raise Cancer Risk? What the Trials Show

Does Adderall XR raise cancer risk?

The two Adderall XR trials cited here measured ADHD symptom scores: 3 weeks in children and 4 weeks in adults [2][3]. Rating-scale trials of that length cannot show whether a drug changes cancer risk over years. They do not answer the question either way.

What the immediate-release Adderall label lists

The label's warnings cover abuse, misuse and addiction (boxed), serious cardiac disease, rises in blood pressure and heart rate, psychiatric reactions, growth suppression in children, seizures, peripheral vasculopathy including Raynaud's phenomenon, serotonin syndrome, and tics [1]. Its adverse reactions section includes cardiovascular, psychiatric, eye, gastrointestinal, allergic and musculoskeletal reactions, among them myocardial infarction, isolated reports of cardiomyopathy with chronic amphetamine use, intestinal ischemia, Stevens-Johnson syndrome and toxic epidermal necrolysis, angioedema, anaphylaxis and rhabdomyolysis [1]. Cancer appears in none of these sections.

That is the label for the immediate-release Adderall tablets, effective May 2024 [1]. The Adderall XR label itself was not checked for cancer content here, so the immediate-release label's silence says nothing about it. Adderall XR is a separate extended-release capsule product, approved in 2001 under its own application [4]. The pediatric trial describes it as a two-component extended-release formulation designed to last through the day with one morning dose [2].

What the Adderall XR trials measured

The pediatric trial randomized 584 children aged 6 to 12 at 47 sites to 10, 20 or 30 mg once daily or placebo for 3 weeks, with teacher and parent Conners Global Index scores as the outcomes [2]. The adult trial randomized 255 adults to 20, 40 or 60 mg per day or placebo for 4 weeks. ADHD Rating Scale scores fell in every dose group, with a mean effect size of 0.8 [3].